Women's Health Weekly — 2026-06-09
A landmark publication in The Lancet has officially recognized the broader metabolic impacts of PCOS by renaming it PMOS (Polyendocrine Metabolic Ovarian Syndrome). Meanwhile, Apple has expanded its Health app to track menopause and perimenopause symptoms, and new research from the University of Vermont highlights critical brain changes during menopause—reinforcing that this transition is a neurological milestone, not just a reproductive one.
Key Highlights
PCOS Renamed to PMOS in Historic Shift
In a new landmark publication in The Lancet, a global effort involving academic, clinical, and patient organizations has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS)—reflecting decades of evidence that this condition affects far more than reproductive health. This renaming acknowledges the whole-body metabolic and endocrine impacts that have long been underrecognized by the medical community.
Apple Health Now Tracks Menopause and Perimenopause
Apple announced a major expansion of its Health app at WWDC 2026, adding dedicated menopause and perimenopause tracking features. Users can now log symptoms and receive cycle alerts—expanding the app's cycle tracking capabilities beyond fertility and menstrual periods. The update aims to normalize menopause symptom documentation and provide users with data to share with healthcare providers.
Menopause Triggers Significant Brain Changes, New Research Confirms
Researchers at the Robert Larner, M.D. College of Medicine at the University of Vermont have documented measurable changes in brain function during menopause, underscoring that this life stage represents a critical neurological phase—not merely a reproductive milestone. The findings reinforce the growing medical consensus that menopause deserves recognition as a transformative period affecting cognitive health and overall brain aging.
Analysis
This week's convergence of news signals a fundamental shift in how medicine recognizes women's health across the lifespan. The PMOS rename is particularly significant because it formalizes what researchers and patients have long known: ovarian dysfunction triggers cascading metabolic and endocrine effects that affect insulin regulation, cardiovascular health, and long-term disease risk. This reclassification could reshape clinical practice, research priorities, and insurance coverage decisions.
Simultaneously, the addition of menopause tracking to Apple's ubiquitous Health app democratizes symptom data collection and empowers women to quantify experiences—like hot flashes, sleep disruption, and mood changes—that have historically been dismissed or minimized. When paired with neuroscience evidence that menopause reshapes brain function, these tools position midlife women's health as a major frontier in precision medicine and digital health innovation.
What to Watch
- Clinical Practice Evolution: Watch for updates to clinical guidelines and diagnostic criteria following the PMOS rename, particularly regarding metabolic screening and earlier intervention protocols.
- Digital Health Adoption: Monitor how widely Apple's menopause tracking feature is integrated into clinical workflows and whether other health platforms (Fitbit, Oura, etc.) follow with similar tools.
- Brain Health Research: Track emerging studies linking midlife hormonal changes to cognitive aging—especially as researchers work to understand whether hormone therapy interventions can preserve neurological health.
Women's Health Weekly curates the week's most significant developments in women's reproductive health, midlife medicine, and health technology. For questions or submissions, contact the editorial team.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
